Sign In
Buy CRSP
$46.99
-0.790 (-1.65%)
At Close: Jul 20, 2026
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
07:30am, Monday, 26'th Aug 2024
Viking and CRISPR are both doing work in expanding and lucrative areas. They could deliver market-beating returns if they can avoid major headwinds.
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
12:46pm, Monday, 19'th Aug 2024
Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.
Crispr's Casgevy Launch: Promising Start, Uncertain Future
06:08am, Wednesday, 14'th Aug 2024
CRISPR Therapeutics' stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy,
3 Gene Editing Stocks with Potential to Transform Medicine
10:19am, Friday, 09'th Aug 2024
Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disord
7 Biotech Stocks to Buy for Their Game-Changing Potential
06:00am, Thursday, 08'th Aug 2024
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.
Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
10:41am, Wednesday, 07'th Aug 2024
Crispr Therapeutics AG reported no revenues from Casgevy in Q2 earnings, but noted positive progress with over 35 authorized treatment centers activated globally. Casgevy's complex treatment journey i
The 3 Best Gene Editing Stocks to Buy in August 2024
09:00am, Wednesday, 07'th Aug 2024
Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030.
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
11:41am, Tuesday, 06'th Aug 2024
CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates
06:25pm, Monday, 05'th Aug 2024
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.49 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to loss of $0.98 per share a year ago.
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
04:01pm, Monday, 05'th Aug 2024
-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July-
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker
06:22am, Sunday, 04'th Aug 2024
CRISPR Therapeutics' first approval should go on to become massively successful. This approval was a major breakthrough in the area of gene editing.
10 Best Small and Mid-Cap Stocks to Consider Buying in August
06:30am, Thursday, 01'st Aug 2024
Big tech stocks cooled off in July, while smaller growth companies rallied. An anticipated rate cut could amplify this trend reversal in August and beyond.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
09:45am, Wednesday, 31'st Jul 2024
Cathie Wood bought shares of Guardant Health, Oklo, and CRISPR Technologies on Tuesday. Guardant is the only one of the three trading higher this year, fueled by the prospects of a new colorectal canc
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
10:01am, Tuesday, 30'th Jul 2024
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Top 3 Cathie Wood Stocks to Buy Now: Summer 2024
04:00pm, Monday, 29'th Jul 2024
Investing guru Cathie Wood still attracts a large following. Although the founder of the Ark Invest family of exchange-traded funds (ETFs) is trailing the market by a wide margin in 2024.
